Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TNF | P01375 | 5/20 | 0.51 |
| ▸ | CSF1R | P07333 | 1/20 | 0.42 |
| ▸ | PLK1 | P53350 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | NPC1 | O15118 | 2/20 | 0.37 |
| ▸ | MMP13 | P45452 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.36 |
| ▸ | NPBWR1 | P48145 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | HTR1A | P08908 | 2/20 | 0.36 |
| ▸ | DRD2 | P14416 | 1/20 | 0.36 |
| ▸ | DRD3 | P35462 | 1/20 | 0.36 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17181483 | 0.95 | TNF (0.47) | TNFCSF1RPLK1NPC1MMP13 | |
| SCHEMBL15671101 | 0.89 | TNF (0.47) | TNFCSF1RALDH1A1KDM4EGAA | |
| SCHEMBL17192040 | 0.87 | KDM4E (0.46) | TNFCSF1RALDH1A1KDM4EGAA | |
| SCHEMBL15670882 | 0.87 | SYK (0.42) | TNFCSF1RPLK1ALDH1A1NPC1 | |
| SCHEMBL15680502 | 0.82 | CSF1R (0.40) | TNFCSF1RPLK1ALDH1A1NPC1 | |
| SCHEMBL17181555 | 0.82 | TNF (0.39) | TNFCSF1RPLK1NPC1MMP13 | |
| SCHEMBL15670874 | 0.81 | TNF (0.72) | TNFALDH1A1MAPTHTR1ADRD2 | |
| SCHEMBL17181429 | 0.80 | TNF (0.38) | TNFCSF1RPLK1ALDH1A1NPC1 | |
| SCHEMBL15671003 | 0.77 | HDAC6 (0.52) | TNFCSF1RNPC1MMP13P2RX3 | |
| SCHEMBL15671045 | 0.75 | TNF (0.67) | TNFALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10174053-B2 | 2 substituted cephem compounds | GLAXO GROUP LIMITED (GB) | 2019-01-08 | — | — | US | disclosed |
| US-10174053-B2 | 2 substituted cephem compounds | GLAXO GROUP LIMITED (GB) | 2019-01-08 | — | — | US | disclosed |
| US-20170281532-A1 | 2 SUBSTITUTED CEPHEM COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2017-10-05 | — | — | US | disclosed |
| US-20150299223-A1 | 2-SUBSTITUTED CEPHEM COMPOUNDS | GLAXO GROUP LTD (GB) | 2015-10-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170281532-A1 | 2 SUBSTITUTED CEPHEM COMPOUNDS | CEP170, CES2, CMBL | TNF 2990/4885CSF1R 2327/4885PLK1 2169/4885 |
| US-20150299223-A1 | 2-SUBSTITUTED CEPHEM COMPOUNDS | CEP170, ABL1, CEPT1 | TNF 1673/4885CSF1R 1061/4885PLK1 3051/4885 |
| US-10174053-B2 | 2 substituted cephem compounds | CEP170, CES2, CMBL | TNF 2990/4885CSF1R 2327/4885PLK1 2169/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.